

IMSUT Hospital

Department of Oncology and General Medicine

腫瘍・総合内科

Head, Professor	Narikazu Boku, M.D., D.M.Sc.
Assistant Professor	Keisuke Baba, M.D., D.M.Sc.
Assistant Professor	Gota Fujisawa, M.D., D.M.Sc.
Assistant Professor	Naoko Fukui, M.D., D.M.Sc.

教授	博士(医学)	朴	成
助教	博士(医学)	馬	場
助教	博士(医学)	藤	澤
助教	博士(医学)	福	井
			直
			剛
			介
			太
			子

Summary

The department of oncology and general medicine started in July 2021 taking over the department of general medicine. The members specialize in medical oncology, and endocrinology/metabolism. Our aim is to practice total human medical care for patients with malignant disease and endocrine/metabolic disease in collaboration with other departments in the IMSUT hospital and conduct clinical research.

1. Medical Oncology.

Boku N, Baba K, Fujisawa G

Patients with various, mainly gastrointestinal, cancers were treated with standard chemotherapy including cytotoxic agents, molecular target agents, immune checkpoint inhibitors, in combination with surgery and radiation therapy. With help of the special patient support team consisting of nurses, pharmacists and nutritionists, the quality of patient care during chemotherapy has been improved. The number of chemotherapy cases has been increasing: 105 chemotherapy regimens for 68 patients in 2025, including 57 new patients. We enrolled 42 patients to 14 prospective multi-institutional clinical trials (2 patients in 2 clinical trials for new drug development) (Table). As a principal investigator, we are now conducting a multi-institutional randomized phase III trial comparing topical diclofenac with placebo for preventing capecitabine induced hand-foot syndrome, for which we have achieved a grant from the Japan Agency for Medical Research and Development (AMED). This

trial has been launched in March 2025. We are now planning a phase II trial to investigate the efficacy and safety of zolbetuximab (anti-Claudin antibody) in combination with 5-fluorouracil plus leucovorine (mFOLOFX6) for Claudin-18.2 (+) advanced gastric cancer patients complicated with severe peritoneal metastasis as a principal investigator in the West Japan Oncology Group. In addition, we are now developing a new data capturing system using a patient's smart phone for patient registration and monitoring the real world data. As for basic research, we investigate the synergism of molecular target agents based on the phosphoproteomic analysis to develop new personalized treatment, for which we have obtained the Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science.

2. Endocrinology and Metabolism.

Fukui N

In the field of endocrinology and metabolism, clinical care is provided mainly for endocrine disorder-

Table: Lost of on-going clinical trials

Phase I/II study of S-1 at the dose recommended by the BBT formula in combination with oxaliplatin and nivolumab for advanced gastric cancer
Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus trifluridine/tipiracil in previously treated advanced gastric adenocarcinoma
A phase II study of mFOLFOX6 + Nivolumab as first-line treatment in gastric cancer with severe peritoneal metastasis
A prospective study of triplet therapy with encorafenib, Binimetinib and cetuximab for early relapse BRAF V600E-mutated Stage II/III colorectal cancer during or after adjuvant chemotherapy
A randomized phase III study to compare ONO-4538 in combination with ipilimumab, fluoropyrimidine- and platinum-based chemotherapy versus chemotherapy in advanced gastric cancer
A randomized phase II study to compare ONO-4578 with placebo in combination with nivolumab, fluoropyrimidine- and platinum- based chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in advanced gastric cancer
A randomized phase III study to compare PS-SOD with placebo for preventing peripheral neuropathy in colorectal cancer patients receiving adjuvant chemotherapy with mFOLFOX6
A phase I study of a recombinant measles virus for Nectin-4 (+) tumor
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT)
A phase II trial of Zolbetuximab combination with CAPOX or FOLFOX for HER2-negative and Claudin 18.2-positive gastric cancer early relapsed during or after adjuvant chemotherapy (OGSG2501)
A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination with other Anti-cancer Therapies in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103)
A single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
A Randomized Phase II Clinical Trial Evaluating the Safety and Efficacy of Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in Patients with HER2-negative and CLDN18.2-positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal junction cancer
Randomized Phase II trial Evaluating the Efficacy of Zolbetuximab in the second-line for Claudin18.2 Positive Advanced Gastric/EGJ Cancer Patients Previously Treated with Zolbetuximab and Platinum-Based Chemotherapy (ZELDA trial)

ders, including diabetes mellitus, thyroid diseases, adrenal disorders, pituitary diseases, and disorders of bone and calcium metabolism, taking not only to disease status but also to social background and continuity of care into consideration, with an emphasis on comprehensive endocrine and metabolic management.

In diabetes care, treatment strategies were tailored according to individual backgrounds and comorbid conditions, and clinical practice was conducted in collaboration with nurses, registered dietitians, and pharmacists. Through integrated education, nutritional guidance, and adjustment of pharmacological therapy, glycemic management was provided for cases requiring intensive metabolic control such as the perioperative period and steroid administration.

As for endocrine diseases, diagnosis and treat-

ment were performed mainly for pituitary, adrenal, and thyroid disorders, based on integrated assessments using imaging studies and endocrinological examinations. Endocrine stimulation and suppression tests were conducted after careful consideration of indication. For chronic conditions requiring long-term management, medication adherence is enhanced through education and sharing information among multiple healthcare professionals.

From an academic perspective, daily clinical data related to endocrine and metabolic diseases are systematically recorded to identify clinical issues for future research activities.

Publications

1. Fujisawa G, Ishibashi R, Yoshida S, Kondo R, Hata M, Oya Y, Odawara N, Nakada A, Komine Y, Hakuta R, Takahara N, Suzuki N, Nakai Y, Isayama H, Fujishiro M. Safety and Effectiveness of Colonic Stenting for Ileocecal Valve Obstruction and Usefulness of Two-Step Strategy: Single-Center Retrospective Study. *J Clin Med*. 14(3):826, 2025.
2. Suzuki N, Odawara N, Fujisawa G, Ishibashi R, Hata M, Oya Y, Tamada K, Hayashi T, Abe S, Miyakawa Y, Hayakawa Y, Shinozaki-Ushiku A, Ushiku T, Boku N, Fujishiro M. Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED). *Intern Med*. 64(1): 101-107, 2025.
3. Nakashima K, Harashima S, Kaneko R, Tanaka R, Abe M, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Satomi E, Takeda M, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Sasaki H. Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology. *Int J Clin Oncol*. 30(1): 17-26, 2025.
4. Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakamura N, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Nakajima TE. Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. *Int J Clin Oncol*. 30(1):27-39, 2025.
5. Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, Kurokawa Y, Boku N, Terashima M, Yoshikawa T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study). *Jpn J Clin Oncol*. 55(3):304-310, 2025.
6. Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG). Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS. *Gastric Cancer*. 28(2):301-308, 2025.
7. Hirano H, Takahashi N, Amanuma Y, Suzuki N, Takahara D, Kawakami T, Kudo-Saito C, Nagashima K, Boku N, Kato K, Shoji H. Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE). *BMC Cancer*. 25(1):201, 2025.
8. Machida N, Okumura T, Boku N, Kishimoto J, Nishina T, Suyama K, Ohde Y, Shinozaki K, Baba H, Tokunaga S, Kawakami H, Tsuda T, Kotaka M, Okuda H, Yasui H, Yamazaki K, Hironaka S, Muro K, Hyodo I. A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). *Cancer*. 131(7): e35807, 2025.
9. Baba K, Suzuki N, Imamura CK, Booka E, Takeuchi M, Takahara D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito K, Tanoue K, Baba E, Nagashima K, Boku N. A phase I/II trial evaluating the safety of increased-dose S-1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. *BMC Cancer*. 25(1): 675, 2025. doi: 10.1186/s12885-025-14084-1.
10. Miyakawa Y, Ishigaki Y, Suzuki N, Endo G, Suzumori C, Hayashi T, Tamada K, Iwata T, Fujisawa G, Hayakawa Y, Boku N, Fujishiro M. Rare Case of Severe Pancreatitis induced by Encorafenib and Cetuximab in BRAF V600E-Positive Colorectal Cancer. *Intern Med*. 64(22):3252-3256, 2025.
11. Baba K, Tanie T, Matsubara Y, Hirata Y, Ikematsu H, Boku N. Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report. *Case Rep Oncol*. 18 (1): 286–295, 2025.
12. Iimura Y, Ishiguro H, Hashimoto H, Nojima M, Oyamada S, Mori K, Ariyoshi K, Kuroda S, Hirakawa S, Fujiwara N, Yokota T, Zenda S, Matsuoka H, Boku N. A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT). *Int J Clin Oncol*. 30(8):1553-156, 2025.
13. Kawakami H, Kadowaki S, Makiyama A, Tsuda

- M, Hirata K, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S, Kobayashi Y, Kakimi K, Chiba Y, Boku N, Hyodo I, Muro K. Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer. *J Clin Oncol.* 43(19):2184-2195, 2025.
14. Sakai D, Kadowaki S, Kawabata R, Hara H, Satake H, Takahashi M, Takeno A, Imai H, Minashi K, Kawakami T, Boku S, Matsuyama J, Sakamoto Y, Sawada K, Kataoka M, Kawakami H, Shimokawa T, Boku N, Satoh T. Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBERG Trial. *J Clin Oncol.* 43(19):2196-2207, 2025.
 15. Yamagata Y, Furuta M, Notsu A, Yasui H, Makuuchi R, Yamada T, Ishida M, Tsuji K, Baba S, Tokumoto N, Haruta S, Watanabe M, Hamakawa T, Kawachi Y, Sugisawa N, Yabusaki H, Kawabata R, Kurokawa Y, Boku N, Terashima M, Machida N, Yoshikawa T. Efficacy of nodal dissection for locoregional gastric neuroendocrine carcinoma: a multicenter retrospective observational study. *Gastric Cancer.* 28(5): 1004-1016, 2025.
 16. Iimura Y, Baba K, Furukawa N, Ishibashi M, Sasuga C, Ahiko Y, Monma S, Sakuyama N, Aikou S, Shida D, Nojima M, Kuroda S, Boku N. A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). *Int J Clin Oncol.* 30(11):2316-2324, 2025.
 17. Osumi H, Wakatsuki T, Ooki A, Chin K, Shoji H, Ogura M, Nakayama I, Yamamoto N, Hirano H, Hara H, Minashi K, Shinozaki E, Kato K, Ishizuka N, Kitano S, Takeuchi K, Boku N, Yamaguchi K, Takahari D. Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High). *Ther Adv Med Oncol.* 17: 17588359251367344, 2025.
 18. Fujiya K, Tokunaga M, Tone K, Nakanishi K, Tanaka R, Sato S, Kitadani J, Kakiuchi Y, Nakayama I, Hato S, Nunobe S, Fujitani K, Kurokawa Y, Boku N, Yoshikawa T. A Multicenter Collaborative Survey of Peritoneal Lavage Cytology in Gastric Cancer Surgery: Interinstitutional Methodological Differences and Positive Rate. *Ann Surg Open.* 6(3):e607, 2025.
 19. Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Ichikawa H, Boku N. IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer. *J Transl Med.* 17;23(1):1125, 2025.
 20. Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Boku N. Peripheral SNCA + cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer. *Discov Oncol.* 2025 Oct 22;16(1):1951.
 21. Imaizumi J, Shida D, Boku N, Igaki H, Miyakita Y, Kitabayashi I, Narita Y, Itami J, Takashima A, Kanemitsu Y. Development and validation of a prognostic nomogram for survival in patients with brain metastases from colorectal cancer. *Sci Rep.* 6; 15(1): 38887, 2025.
 22. Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Nagashima F, Narita Y, Yamamoto Y, Kizawa R, Muro K, Boku N. The FSTL1-DI-P2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. *Cancer Immunol Immunother.* 18; 74(12):379, 2025.
 23. Shoji H, Takahari D, Ooki A, Hirano H, Okita N, Nagashima K, Adachi J, Yamaguchi K, Kato K, Boku N. Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer. *Sci Rep.* 2 16(1):692, 2025.